

Tytonis announces release of the book “Pharmaceutical Proteins – Formulation, Analytics & Delivery”

February 4th, 2010, Alkmaar, The Netherlands

Tytonis B.V. (“Tytonis”) announces today that the book “Pharmaceutical Proteins – Formulation, Analytics and Delivery” in the series APVpharmareflexions has been published and is now available for ordering through the internet address of the ECV publisher house: www.ecv.de/ecv/catalog/product_info.php?products_id=3011&language=en. The book has been edited by Dr. Hanns-Christian Mahler, Hoffmann-La Roche, Prof. Gerrit Borchard, University of Geneva and Dr. Henrik L. Luessen, Tytonis BV. Moreover, about 30 internationally highly recognized experts in the field have contributed through their chapters to the book.

The book covers principal topics on the basics in protein chemistry in order to understand the particular behavior of such molecules and their analytical characterization. Particular issues related to stability aspects and aggregation have been addressed as well. As a second area the book then discusses the formulation of biopharmaceuticals and drying techniques to stabilize proteins, as well as further specific areas such as highly concentrated protein formulations, primary packaging materials, and manufacturing challenges. In addition, the in vivo fate of biopharmaceuticals considering their pharmacokinetic/pharmacodynamic behavior is addressed in this section. Since a second generation of biopharmaceutical products are facing market authorization or are already launched, some chapters were also dedicated to the polyethylene glycolation of proteins, targeting aspects and still evolving technologies to modify delivery of such protein therapeutics by depot formulations or lipid complexation. Considering its importance of safety and efficacy, also immunogenicity and considerations for product development have been addressed. Last but not least, two chapters address regulatory aspects that pharmaceutical and biopharmaceutical scientists should keep in mind when being involved in the development of biopharmaceuticals.

Tytonis, founded in 2006 by Dr. H. Luessen (www.tytonis.com), is a privately owned company providing advisory services to a selected group of pharmaceutical companies to support them in Corporate/Business Development, Licensing, Valuation, Portfolio Strategy, Pharmaceutical Product Development and Drug Delivery related topics. Tytonis also operates within a highly reputed expert network of former industrial executives and distinguished experts, called “Pharma at Work”.

Dr. Henrik Luessen, CEO of Tytonis, says: *“It was a hard piece of work for everyone and finally it took more than two years to complete this project. The book would not have been possible without the strong support of Hanns-Christian Mahler and Gerrit Borchard and all the authors who dedicated a significant part of their free available time to assure the most updated state-of-the-art into their chapter contributions. The non-profit organization APV (International Association of Pharmaceutical Technology) that hosted several times seminars on the topic of Pharmaceutical Protein Formulations has furthermore supported the project with their strong industrial and academic key opinion leaders. I would love to take this opportunity to thank everyone who contributed to make this book valuable for those that are involved in the development process of pharmaceutical protein products.”*

For further information, please contact:

Henrik L. Luessen, Tytonis BV, telephone number +31 (6) 215 66 415 or e-mail henrik.luessen@tytonis.com.

The next seminar on Protein Formulation, where some of the book authors will also present their topic in person will be held in Basel on April 22-23rd, 2010. The program can be downloaded through the APV website: www.apv-mainz.de/pdf_veranstaltungen/6290.pdf.

This document may contain certain forward-looking statements relating to the business, financial performance and results of Tytonis B.V. and the industry in which it operates. These statements are based on Tytonis' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements.